HC Wainwright Reaffirms Buy Rating for Abeona Therapeutics (NASDAQ:ABEO)
Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Wednesday, October 16th, AnalystRatings.com reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 470.34% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the company. Maxim Group cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. ValuEngine upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Royal Bank of Canada lowered their target price on Abeona Therapeutics to $16.00 and set a “posi ...